Study S000689

Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01843075
Acronym: ELAD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 204
Start: 2014-01
Primary completion: 2019-12
Lead sponsor: Imperial College London
Conditions: Alzheimer's Disease
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The change in cerebral glucose metabolic rate [12 months]

Linked records (10)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011033	Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Edison P, Nature medicine	2026	Randomized trial	PMID 41326666 DOI	cites ClinicalTrials.gov:NCT01843075; registry reference DERIVED:41326666
R0017378	Role of liraglutide in Alzheimer's disease pathology. Vargas-Soria M, Alzheimer's research & therapy	2021	Other trial	PMID 34118986 DOI	cites ClinicalTrials.gov:NCT01843075
R0052083	Evaluation of liraglutide in the treatment of Alzheimer's disease Paul Edison, Alzheimer s & Dementia	2021	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01843075
R0050484	Behavioural symptoms in Alzheimer’s disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism Grazia Daniela Femminella, Alzheimer s & Dementia	2020	Other trial	DOI	cites ClinicalTrials.gov:NCT01843075
R0017419	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Femminella GD, Trials	2019	Protocol	PMID 30944040 DOI	cites ClinicalTrials.gov:NCT01843075; registry reference DERIVED:30944040
R0049247	P2‐358: INSULIN RESISTANCE INFLUENCES HIPPOCAMPAL GLUCOSE METABOLISM RATHER THAN HIPPOCAMPAL VOLUME IN NON‐DIABETIC ALZHEIMER'S DISEASE PATIENTS Grazia Daniela Femminella, Alzheimer s & Dementia	2019	Other trial	DOI	cites ClinicalTrials.gov:NCT01843075
R0052821	P3‐328: DOES INSULIN RESISTANCE INFLUENCE WHITE MATTER LESIONS IN NON‐DIABETIC AD SUBJECTS? Grazia Daniela Femminella, Alzheimer s & Dementia	2019	Other trial	DOI	cites ClinicalTrials.gov:NCT01843075
R0028596	Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment. Foltynie T, Movement disorders clinical practice	2018	Randomized trial	PMID 30800701 DOI	cites ClinicalTrials.gov:NCT01843075
R0052696	P3‐225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON‐DIABETIC ALZHEIMER'S PATIENTS Grazia Daniela Femminella, Alzheimer s & Dementia	2018	Other trial	DOI	cites ClinicalTrials.gov:NCT01843075
R0018678	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Muscogiuri G, Trends in endocrinology and metabolism: TEM	2017	Narrative review	PMID 27871675 DOI	cites ClinicalTrials.gov:NCT01843075; registry reference DERIVED:27871675